Literature DB >> 9915329

Inhibitory effects of diazepam and midazolam on Ca2+ and K+ channels in canine tracheal smooth muscle cells.

M Yamakage1, T Matsuzaki, N Tsujiguchi, Y Honma, A Namiki.   

Abstract

BACKGROUND: Benzodiazepines have a direct bronchodilator action in airway smooth muscle, but the mechanisms by which these agents produce muscle relaxation are not fully understood. The current study was performed to identify the effects of the benzodiazepines diazepam and midazolam on Ca2+ and K+ channels in canine tracheal smooth muscle cells.
METHODS: Whole-cell patch-clamp recording techniques were used to evaluate the effects of the benzodiazepines diazepam (10(-8) to 10(-3) M) and midazolam (10(-8) to 10(-3) M) on inward Ca2+ and outward K+ channel currents in dispersed canine tracheal smooth muscle cells. The effects of the antagonists flumazenil (10(-5) M) and PK11195 (10(-5) M) on these channels were also studied.
RESULTS: Each benzodiazepine tested significantly inhibited Ca2+ currents in a dose-dependent manner, with 10(-6) M diazepam and 10(-5) M midazolam each causing approximately 50% depression of peak voltage-dependent Ca2+ currents. Both benzodiazepines promoted the inactivated state of the channel at more-negative potentials. The Ca2+-activated and voltage-dependent K+ currents were inhibited by diazepam and midazolam (> 10(-5) M and > 10(-4) M, respectively). Flumazenil and PK11195 had no effect on these channel currents or on the inhibitory effects of the benzodiazepines.
CONCLUSIONS: Diazepam and midazolam had inhibitory effects on voltage-dependent Ca2+ channels, which lead to muscle relaxation. However, high concentrations of these agents were necessary to inhibit the K+ channels. The lack of antagonized effects of their antagonists is related to the non-gamma-aminobutyric acid-mediated electrophysiologic effects of benzodiazepines on airway smooth muscle contractility.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9915329     DOI: 10.1097/00000542-199901000-00026

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  Guideline-oriented perioperative management of patients with bronchial asthma and chronic obstructive pulmonary disease.

Authors:  Michiaki Yamakage; Sohshi Iwasaki; Akiyoshi Namiki
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

2.  Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors.

Authors:  Damien E Earl; Elizabeth I Tietz
Journal:  J Pharmacol Exp Ther       Date:  2011-01-24       Impact factor: 4.030

3.  Effects of L-type Ca2+ channel modulation on direct myocardial effects of diazepam and midazolam in adult rat ventricular myocytes.

Authors:  Noriaki Kanaya; Paul A Murray; Derek S Damron
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

4.  K+ channels and their effects on membrane potential in rat bronchial smooth muscle cells.

Authors:  Xiansheng Liu; Yongjian Xu; Zhenxiang Zhang; Wang Ni
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

5.  Commonly used intravenous anesthetics decrease bladder contractility: An in vitro study of the effects of propofol, ketamine, and midazolam on the rat bladder.

Authors:  Canan Ceran; Arzu Pampal; Ozgur Goktas; H Kutluk Pampal; Ercument Olmez
Journal:  Indian J Urol       Date:  2010-07

6.  Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action.

Authors:  Nadine Vonderlin; Fathima Fischer; Edgar Zitron; Claudia Seyler; Daniel Scherer; Dierk Thomas; Hugo A Katus; Eberhard P Scholz
Journal:  Drug Des Devel Ther       Date:  2014-11-07       Impact factor: 4.162

7.  Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action.

Authors:  Nadine Vonderlin; Fathima Fischer; Edgar Zitron; Claudia Seyler; Daniel Scherer; Dierk Thomas; Hugo A Katus; Eberhard P Scholz
Journal:  Drug Des Devel Ther       Date:  2015-02-16       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.